scispace - formally typeset
N

Naoto T. Ueno

Researcher at University of Texas MD Anderson Cancer Center

Publications -  390
Citations -  13778

Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.

Papers
More filters
Journal ArticleDOI

Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?

TL;DR: The frequency and factors associated with pathological node-negativity (ypN0) in IBC were described and one-third of patients with IBC who received NAC and MRM had pathologically negative nodes.
Journal ArticleDOI

Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.

TL;DR: The results suggest that patients who have HR-positive/HER2-negative residual disease after taxane-based neoadjuvant chemotherapy may still benefit from palbociclib in combination with other regimens, such as endocrine therapies, for adjuvant therapy.
BookDOI

Inflammatory breast cancer: An update

TL;DR: Book of inflammatory breast cancer an update, as an amazing reference becomes what you need to get, as a source that may involve the facts, opinion, literature, religion, and many others are the great friends to join with.
Journal ArticleDOI

The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.

TL;DR: The role of modified radical mastectomy (MRM) in patients with de novo stage IV inflammatory breast cancer (IBC) remains controversial. as discussed by the authors evaluated the impact of MRM on outcomes in this population.
Posted ContentDOI

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.

TL;DR: None of the patients was able to complete the planned 10 cycles due to the disease progression, and future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.